Abstract
Gene transfer as applied to human cancers is a rapidly evolving and encouraging discipline. As the experience with these new therapeutic techniques grows, so does the awareness of the tolerable toxicities and the potential therapeutic opportunities. Currently many laboratories are aggressively pursuing new vector delivery systems and new therapeutic genes thereby increasing the spectrum of tumor types in clinical trials. With this explosive investigative effort, two early major themes have emerged. First, increasing evidence indicates that the gene products can have anti-tumor efficacy. Second, the transfer of genes to target tumor cells for in vivo expression has so far been found safe with acceptable toxicity. Certainly this emerging technology is creating great enthusiasm and apparent promise for cancer therapeutics.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Asher, A.L., Mule, J.J., Kasid, A. et al. (1991) Murine tumor cells transduced with the gene for tumor necrosis factor-α. J. Immunol., 146, 3227–34.
Baker, S.J., Markowitz, S., Fearon, E.R. et al. (1990) Suppression of human colorectal carcinoma cell growth by wild-type p53. Science, 249, 912–15.
Bi, W.L., Parysek, L.M., Warnick, R. and Stambrook, P.J. (1993) In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy. Human Gene Ther., 4, 725–32.
Brenner, M.K., Furman, W.L., Santana, V.M. et al. (1992) Phase I study of cytokine gene modified autologous neuroblastoma cells for treatment of relapsed/ refractory neuroblastoma. Human Gene Ther., 3, 665–76.
Brenner, M.K., Rill, D.R., Moen, R.C. et al. (1993) Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet, 341, 85–6.
Caruso, M., Panis, Y., Gagandeep, S. et al. (1993) Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc. Natl Acad. Sci. USA, 90, 7024–8.
Chen, S-H., Shine, H.D., Goodman, J.C., Grossman, R.G. and Woo, S.L.C. (1994) Gene therapy for brain tumors: regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. Proc. Natl Acad. Sci. USA, 91, 3054–7.
Colombo, M.P. and Forni, G. (1994) Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now? Immunology Today, 15, 48–51.
Culver, K., Ram, Z., Walbridge, S. et al. (1992) In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science, 259, 1550–2.
Culver, K.W., Van Gilder, J., Link, C.J. et al. (1993) Gene therapy for the treatment of malignant brain tumors with in vivo tumor transduction with the herpes simplex thymidine kinase gene/ganciclovir system. Human Gene Ther., 5, 343–77.
Elion, G.B. (1980) The chemotherapeutic exploitation of virus-specified enzymes. Adv. Enz. Regul., 18, 53–66.
Freeman, S.M., Abboud, C.N., Whartenby, K.A. et al. (1993) The ‘bystander effect’: tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res., 53 5274–83.
Gansbacher, B., Houghton, A., Livingston, V. et al.(1992a) A pilot study of immunization with HLA-A2 matched allogeneic melanoma cells that secrete interleukin-2 in patients with metastatic melanoma. Human Gene Ther., 3, 677–90.
Gansbacher, B., Motzer, R., Houghton, A. et al .(1992b) A pilot study of immunization with interleukin-2 secreting allogeneic HLA-A2 matched renal cell carcinoma cells in patients with advanced renal cell carcinoma. Human Gene Ther., 3, 691–703.
Huber, B.E., Richards, C.A. and Krenitsky, T.T. (1993) In vivo antitumor activity of 5-fluorocytosine on human colorectal cells genetically modified to express cytosine deaminase. Cancer Res., 53, 4619–26.
Hwu, P., Yannelli, J., Kriegler, M. et al. (1993) Functional and molecular characterization of tumor-infiltrating lymphocytes transduced with tumor necrosis factor-α cDNA for the gene therapy of cancer in humans. J. Immunol., 150, 4104–15.
Lotze, M.T., Rubin, J.T, Carty, S. et al. (1994) Gene therapy of cancer: a pilot study of IL-4-gene-modified fibroblasts admixed with autologous tumor to elicit an immune response. Human Gene Ther., 5, 41–55.
Miller, A.D. (1990) Retrovirus packaging cells. Human Gene Ther., 1, 5–14.
Moolten, F.L. (1986) Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res., 46, 5276–81.
Moorman, D.W., Butler, D.A., Stanley, J.D. et al. (1994) Survival and toxicity of xenogeneic murine retroviral vector producer cells in liver. J. Surg. Oncol., 57 (3), 152–6.
Nabel, G.J., Chang, A., Nabel, E.G. et al. (1992) Immunotherapy of malignancy by in vivo gene transfer into tumors. Human Gene Ther., 3, 399–410.
Nabel, G.J., Nabel, E.G., Yang, Z. et al. (1993) Direct gene transfer with DNA-liposome complexes in melanoma: expression, biologic activity, and lack of toxicity in humans. Proc. Natl Acad. Sci. USA, 90, 11307–11
Oldfield, E.H., Ram, Z., Culver, K.W. and Blaese, R.M. (1993) A clinical protocol: gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir. Human Gene Ther., 4, 39–69.
Ram, Z., Culver, K.W., Walbridge, S. et al. (1993a) In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res., 53, 83–8.
Ram, Z., Culver, K.W., Walbridge, S., et al. (1993b) Toxicity studies of retroviral-mediated gene transfer for the treatment of brain tumors. J. Neurosurg., 79, 400–7.
Rosenberg, S.A., Aebersold, P., Cornetta, K. et al. (1990) Gene transfer into humans — immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N. Engl. J. Med., 323, 570–8.
Rosenberg, S.A., Kasid, A., Anderson, W.F. et al. (1992) Immunization of cancer patients using autologous cancer cells modified by insertion of the gene for interleukin-2. Human Gene Ther., 3, 75–90.
Tepper, R.I., Pattengale, P.K. and Leder, P. (1989) Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell, 57, 503–12.
Townsend, S.E. and Allison, J.P. (1993) Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science, 259, 368–70.
Trojan, J., Johnson, T.R., Rudin, S.D. et al. (1993) Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin-like growth factor 1 RNA. Science, 259, 94–7.
Tsai, S-C.J., Gansbacher, B., Tait, L., Miller, F.R. and Heppner, G.H. (1993) Induction of antitumor immunity by interleukin-2 gene-transduced mouse mammary tumor cells versus transduced mammary stromal fibroblasts. J. Natl Cancer Inst., 85, 546–53.
Zhang, Y., Mukhopadhyay, T., Donehower, L.A. et al. (1993) Retroviral vector-mediated transduction of K-ras antisense RNA into human lung cancer cells inhibits expression of the malignant phenotype. Human Gene Ther., 4, 451–60.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Moorman, D.W., Culver, K.W. (1995). Gene transfer and cancer chemotherapy. In: Dickson, G. (eds) Molecular and Cell Biology of Human Gene Therapeutics. Molecular and Cell Biology of Human Diseases Series, vol 20. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-0547-7_7
Download citation
DOI: https://doi.org/10.1007/978-94-011-0547-7_7
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-4242-0
Online ISBN: 978-94-011-0547-7
eBook Packages: Springer Book Archive